)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Jacobio Pharmaceuticals Group
Jacobio Pharmaceuticals Group (1167) investor relations material
Jacobio Pharmaceuticals Group H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary24 Aug, 2026
Executive summary
Revenue surged 1499.3% year-over-year to RMB730.9 million, driven by major global collaborations with AstraZeneca and licensing/service agreements with Allist for key oncology assets.
Net profit reached RMB600.6 million for H1 2026, reversing a net loss of RMB59.0 million in H1 2025.
Significant pipeline progress: glecirasib (KRAS G12C inhibitor) approved and commercialized in China; JAB-23E73 (pan-KRAS inhibitor) advanced in clinical trials and out-licensed to AstraZeneca with a US$100 million upfront payment.
Strengthened global partnerships, notably with AstraZeneca and Allist, to expand R&D and commercialization.
Announced senior management changes and continued focus on pipeline innovation and global expansion.
Financial highlights
Revenue: RMB730.9 million (up from RMB45.7 million year-over-year).
Gross profit: RMB712.7 million (up from RMB45.7 million year-over-year).
Net profit: RMB600.6 million (vs. net loss of RMB59.0 million year-over-year).
R&D expenses: RMB92.2 million (down 1.1% year-over-year); administrative expenses: RMB18.6 million (flat year-over-year).
Cash and bank balances: RMB1,680.1 million as of June 30, 2026.
Outlook and guidance
Focus on expanding the KRAS and iADC (immunostimulatory ADC) pipelines, with multiple IND applications planned for late 2026.
Continued global development and commercialization partnerships, especially with AstraZeneca for JAB-23E73.
Ongoing clinical trials for key assets in NSCLC, CRC, PDAC, and other solid tumors, with further regulatory submissions and commercialization milestones anticipated.
No interim dividend declared for H1 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Jacobio Pharmaceuticals Group
- Revenue fell, but clinical and partnership milestones drove strategic progress in 2025.1167
H2 2025 - Milestone revenue, narrowed loss, and clinical progress led to a strong cash position.1167H1 2025
- R&D costs fell, no revenue recognized, and key oncology assets advanced to pivotal stages.1167H1 2024
- Revenue surged 145% and net loss narrowed 57% on strong licensing and R&D progress.1167H2 2024
Next Jacobio Pharmaceuticals Group earnings date
H2 20269 Mar, 2027
Jacobio Pharmaceuticals Group
Next Jacobio Pharmaceuticals Group earnings date
H2 20269 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Jacobio Pharmaceuticals Group Co., Ltd. is a Chinese biopharmaceutical company focused on innovative drug discovery and development. It concentrates on oncology and immunology, advancing a pipeline of targeted therapies and immune-oncology treatments. The company uses in-house research platforms and conducts clinical trials both domestically and internationally. The company is headquartered in Beijing, China, and its shares are listed on the HKEX.